| Scientific Session III Chairs: E. Seeman - R. Lederman
| |
| Plenary Lecture 4 Osteoporosis treatments and fracture healing (Speaker: J. Goldhahn)
| |
| Oral Communications 09.30-09.40 OC17
Nitroglycerin improves bone mineral density, bone geometry and bone strength: results from a two-year randomized controlled trial - S. Jamal, C. Hamilton, R. Eastell, S. Cummings
09.40-09.50 OC18
The efficacy of high-dose oral vitamin D3 administered once a year: a randomised, double-blind, placebo-controlled trial (vital D study) for falls and fractures in older women - K. Sanders, A. Stuart, E. Williamson, J. Simpson, M. Kotowicz, G. Nicholson
09.50-10.00 OC19
Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology - J. Koh, S.K. Goh, M.A. Png, A. Ng, T.S. Howe
| |
| Plenary Lecture 5 FRAX, 2 years after its launch (E. McCloskey)
| |
| Oral Communications 10:30-10:40 OC20
Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5mg - D. Black, I. Reid, R. Eastell, C. Bucci Rechtweg, G. Su, T.F. Hue, K. Lyles, S. Boonen
10.40-10.50 OC21
Fractures in obese postmenopausal women: prevalence, skeletal location and risk factors - J. Compston, J. Netelenbos, R. Lindsay, C. Cooper, A. Diéz-Pérez, S. Greenspan, F. Hooven, A. LaCroix, M. Rossini, J. Flahive
10.50-11.00 OC22
Methylation status of the RXRA promoter in umbilical cord predicts childhood bone mineral content - N. Harvey, H. Inskip, B. Emerald, C. Gale, M. Hanson, P. Gluckman, K. Godfrey, C. Cooper, E. Garratt, A. Sheppard, C. McLean, K. Lillycrop, G. Burdge, J. Slater-Jefferies, J. Rodford, S. Crozier
11.00-11.10 OC23
Risk factors predictive of joint replacement in a two-year multicentre clinical trial in knee osteoarthritis using MRI: results from over six years of observation - J-P. Raynauld, J. Martel-Pelletier, B. Haraoui, D. Choquette, M. Dorais, L. Wildi, F. Abram, J-P.Pelletier
11.10-11.20 OC24
Sclerostin plays a key role in abnormal Wnt/!-catenin signaling in human osteoarthritic subchondral osteoblasts leading to reduced mineralization - E. Abed, D. Couchourel, A. Delalandre, J. Martel-Pelletier, J-P. Pelletier, D. Lajeunesse
11.20-11.30 OC25
Five-year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension - S. Papapoulos, Z. Man, D. Mellstrom, S. Radominski, J-Y. Reginster, H. Resch, J. Román, C. Roux, S. Cummings, H. Bone, R. Chapurlat, M. Brandi, J. Brown, E. Czerwinski, N. Daizadeh, A. Grauer, M-A. Krieg, C. Libanati
11.30-11.40 OC26
Poor cortical bone status in men with elevated concentrations of osteoprotegerin - the STRAMBO study - P. Szulc, G. Hawa, S. Boutroy, N. Vilayphiou, M. Schoppet, R. Chapurlat, L. Hofbauer
11.40-11.50 OC27
In balloon kyphoplasty for osteoporotic vertebral body fractures, the potention of reduction is depending on the time to surgery - T. Blattert, C. Günther, S. Glasmacher, C. Josten
| |
| Lunch Symposium - Amgen | GSK Practical aspects in the treatment of osteoporosis - Chairmen: N. Guanabens & S. Papapoulos
| |
| Lunch Symposium - Medtronic Controversies in the treatment of vertebral compression fractures - Chairmen: S. Boonen & C. Bouza
| |
| Meet the Professor Session - Osteoporosis in children and adolescents (E. Seeman, MTP Room 1 - 1st floor)
| |
| Poster Session II (P400 to P688) & Exhibition Viewing | |
| ESCEO-FROMO Symposium Recommendations for the design of clinical trials to be conducted by food and food supplements, in order to be granted the right to use health claims in osteoporosis (in collaboration with GREES) (Chairmen: R. Rizzoli and O. Bruyère)
- Welcome - J.-Y. Reginster
- Why do we need guidelines before granting health claims authorization to food supplement? - V. Coxam
- Regulatory approach of health claims for food supplements in Europe - A. Martin
- Health claims in osteoporosis for food supplements - O. Bruyère
- Discussion - B. Avouac
| |
| ESCEO-FROMO Symposium Generic versus branded medication in osteoporosis: Are they really similar ? (Chairmen: J. D. Adachi – J. A. Kanis)
- Welcome and introduction - J. A. Kanis
- Generic medications: definition and regulatory aspects in Europe - J.-M. Kaufman
- Brand versus generic bisphosphonates: are they equally effective and tolerated - J. Ringe
- Brand versus generic bisphosphonates: implications for patient management - J. D. Adachi
- Discussion - C. Cooper, J.-M. Kaufman, J. Ringe, J. D. Adachi, M. Hiligsmann, J. A. Kanis, J.-Y. Reginster.
- Conclusion - J. A. Kanis.
| |
| Meet the Professor Session - Practical use of vertebral fracture assessment (H. Genant, MTP Room 2 - 1st floor)
- Osteoporosis management after a fracture (S. Boonen, MTP Room 3 - 1st floor)
- Bone effects of biologicals for rheumatoid arthritis (J. Louie, MTP Room 4 - 1st floor)
| |
| Oral Presentation of Selected Posters Moderator: Ego Seeman
14.15-14.20 P325
Effect of oral ibandronate on bone microarchitecture in women with osteopenia: a randomized placebo-controlled trial - R. Chapurlat, M. Laroche, T. Thomas, S. Rouanet, P. Delmas, M-C. De Vernejoul
14.20-14.25 P385
A comparison of case-finding strategies for the management of osteoporosis - E. McCloskey, H. Johansson, J. Compston, A. Oden, J. Kanis
14.25-14.30 P415
Meta-analysis of genome-wide association studies for quantitative ultrasound of the heel: the gefos consortium - A. Moayyeri, N. Wareham, P. Sham, C. Hayward, U. Gyllensten, H. Campbell, A. Uitterlinden, T. Spector, A. Kung, D. Kiel, F. Rivadeneira, Y-H. Hsu, D. Karasik, J. Reeve, Stephen Kaptoge, K. Estrada, S. Brown, S. Xiao, W. Igl, O. Polasek, S. Wilson, K-T. Khaw
14.30-14.35 P420
Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal children - Z. Cole, N. Harvey, M.a Kim, S. Robinson, H. Inskip, K. Godfrey, C. Cooper, E. Dennison
14.35-14.40 P256
Positive impact of both protein intake and physical activity before puberty on biomechanical strength at weight bearing skeletal sites 7.8 yrs later in healthy boys - T. Chevalley, J-P. Bonjour, B. Van Rietbergen, S. Ferrari, R. Rizzoli
14.40-14.45 P151
Incidence of hip fracture in Belgium between 2000 and 2007 and future projections - M. Hiligsmann, O. Bruyère, J. Detilleux, P. Gillet, Y. Parmentier, J-P. Dercq, J. Carton, J-Y. Reginster
|
| Scientific Session IV Chairs: G. Riera - J. Adachi
| |
| Plenary Lecture 6 Epidemiology and outcome of lower limb osteoarthritis and arthroplasty (C. Cooper)
| |
| Oral Communications 15.30-15.40 OC28
Dynamic PET/CT imaging with L-[methyl-11C]methionine after resistance exercise: a novel biomarker of skeletal muscle protein synthesis? - T. Lang, M. Hernandez-Pampaloni, R. Hawkins, Y. Seo, G. Sayre, R. Harnish, T. Streeper, I. Saeed, C. Schreck, S. Dannoon, J. Slater, J. Blecha, H. VanBrocklin
15:40-15:50 OC29
PTH efficacy in bone healing models with T-cell deficient rats - M. Sato, M. Adrian, M.Hamang, A. Harvey, Q. Zeng, Y. Ma
15.50-16.00 OC30
Intermediate molecular weight hyaluronic acid (GO-ON) is superior to the low molecular weight standard preparation (Hyalgan) in symptom control of knee osteoarthritis over 6 months - F. Berembaum, E. Maheu, J. Grifka, S. Cazzaniga, M. D’Amato, G. Giacovelli, X. Chevalier, F. Rannou, P. Ravaud, L. Rovati
16.00-16.10 OC31
LRP5 gene polymorphisms contribute to the heritability of trabecular bone structure - S. Ferrari, T. Chevalley, J-P. Bonjour, R. Rizzoli
16.10-16.20 OC32
Long-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years - J-Y. Reginster, J.M. Kaufman, J-P. Devogelaer, C.L. Benhamou, C. Roux
16.20-16.30 OC33
Updating of fracture incidence rates for the italian version of FRAX® - P. Piscitelli, M.L. Brandi
16.30-16.40 OC34
The effects of rosiglitazone on bone by multiple image modalities in postmenopausal women with type 2 diabetes mellitus - L. Fitzpatrick, B. Kravitz, A. Northcutt, G. Paul, A. Cobitz, A. Nino
| |
| ESCEO-FROMO Symposium Frailty and Sarcopenia: State of the art (Chairmen: R. Rizzoli – J.A. Kanis)
- Welcome and introduction - J.-Y. Reginster
- Definition of frailty syndrome - C. Cooper
- Epidemiology of frailty syndrome - A.A. Sayer
- Pathophysiology of physical frailty: Inflammatory mechanisms - C. Sieber
- Pathophysiology of physical frailty: Hormonal mechanisms - J.-M. Kaufman
- Methodology of evaluation of Sarcopenia and Frailty - G. Abbelan van Kan
- Future pathway for registering therapeutics in Sarcopenia and Frailty - W.J. Evans
- Discussion - J. A. Kanis, R. Rizzoli, J.-M. Kaufman, C. Cooper, A.A. Sayer, C. Sieber, G. Abbelan van Kan, W. J. Evans, R. Adachi, S. Boonen, W. Dere, B. Mitlak, Y. Tsouderos, J.-Y. Reginster.
| |
